TRDA - Entrada Therapeutics, Inc.

Insider activity in TRDA over the last quarter tilts toward selling: insiders offloaded a net 1,209,960 shares worth roughly $8.7M.

Classified under Biotechnology (Health Care sector), TRDA's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	Baker Bros. Advisors LP	4.69M	$42.55M	-
10%	Mpm Bioventures 2018, L.P.	3.89M	$27.70M	-
10%	Mpm Bioventures 2014, L.P.	3.89M	$27.70M	-
10%	5am Ventures V, L.P.	2.78M	$19.07M	-
Dir	Parmar Kush	2.69M	$18.84M	-

Buys and sells only

10 filings · page 2

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jul 31, 2026	Parmar Kush62	Director, 10% Owner	Sell	116,474	$6.93	$807,027.38	-3.9%	-	-
Jul 31, 2026	5am Ventures V, L.P.62	10% Owner	Sell	116,474	$6.93	$807,027.38	-3.9%	-	-
May 20, 2026	Zeiher Bernhardt G	Director	Buy	5,000	$5.86	$29,316.00	New	+20.4%	-
May 4, 2026	Dowden Nathan J70	President &COO	Sale+OE10b5-1	15,000	$15.33	$229,953.00	-7.0%	-54.0%	-
May 4, 2026	Sethuraman Natarajan83	President, Research &Develop.	Sell10b5-1	25,907	$15.39	$398,809.77	-10.7%	-54.0%	-
Apr 1, 2026	Wentworth Kory James61	Chief Financial Officer	Sell10b5-1	2,500	$12.95	$32,375.00	-2.1%	-45.4%	-
Mar 10, 2026	Dowden Nathan J70	President &COO	Sell10b5-1	15,010	$13.04	$195,770.94	-7.0%	-52.6%	-
Mar 10, 2026	Wentworth Kory James61	Chief Financial Officer	Sell10b5-1	16,477	$13.01	$214,378.56	-11.9%	-52.6%	-
Mar 4, 2026	Wentworth Kory James61	Chief Financial Officer	Sell10b5-1	7,988	$12.25	$97,892.14	-5.5%	-46.9%	-
Nov 21, 2025	Wentworth Kory James61	Chief Financial Officer	Sell10b5-1	8,910	$9.98	$88,931.60	-7.5%	+12.9%	-